Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)
Joan L. Walker(Cornell University), Olga B. Ioffe(University of Maryland, Baltimore), Thomas Rutherford(University of South Florida), Janet S. Rader(Medical College of Wisconsin), Steven J. Skates(Massachusetts General Hospital), Gustavo C. Rodriguez(NorthShore University HealthSystem), Paul DiSilvestro(Women & Infants Hospital of Rhode Island), Kelly‐Anne Phillips(The University of Melbourne), John F. Boggess(University of Kentucky), Mildred Ridgway(University of North Carolina at Chapel Hill), Alexander Olawaiye(Magee-Womens Hospital), Mitchell H. Gail(National Institutes of Health), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Mark H. Greene(Cancer Institute (WIA)), David E. Cohn(The Ohio State University), Austin Miller(Roswell Park Comprehensive Cancer Center), Marion Piedmonte(Cleveland Clinic), Noah D. Kauff(Cancer Institute (WIA)), Mark E. Sherman(National Cancer Institute)
Cited by 18
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Revised FIGO staging for carcinoma of the cervix uteri
|International Journal of Gynecology & Obstetrics|2019|1k